Korean Chinese Japanese
  • Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Korean Chinese Japanese
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
Pharma & Bio
Lifestyle

WSI Co., Ltd. Brings Medical Robotics and New Drug Industries into Focus… Setting Its Sights on the “100 Billion Club” by 2028

WSI Co., Ltd.(299170), a company specializing in pharmaceuticals and medical devices, is breaking away from its long-standing distribution-centric business model—which had been heavily reliant on a si…
  • 2026-09-08 08:41:03
  • YU JIN-HEE
Technology

CureStream Aims for ‘AI Pancreas Subscription’ Beyond Insulin Pumps… Targeting an IPO in 2028

CureStream, a developer of insulin pumps, has received approval for its AI-based, fully autonomous insulin delivery algorithm as an independent software medical device and is launching a subscription …
  • 2026-09-08 07:27:03
  • NA EUN-KYUNG
Business·Industry

[Noul Co., Ltd. Deep Seek ②] Mergers of Penny Stocks Are Not the End… 'Triple-Tiered Watch List Risk'

Noul Co., Ltd.(376930)Although the company is proceeding with a 5-to-1 stock consolidation following its designation as a “monitored stock” due to a share price below 1,000 won, the risk of delisting …
  • 2026-09-07 08:31:02
  • KIM SAE-MI
Lifestyle

Mezzion Pharma Co., Ltd. Launches Udenafil Clinical Trials in the U.K. Following Korea and the U.S. … Final Piece of the Puzzle in Place for Fontan Treatment Approval

Mezzion Pharma Co., Ltd.(140410)is expanding the scope of “FUEL-2,” the global Phase 3 clinical trial for udenafil—a drug under development for the treatment of Fontan patients—to the United Kingdom. …
  • 2026-09-07 08:26:01
  • KIM JI-WAN
Technology

GSK Also Bets Up to $1.4 Billion on a New Drug from China… K-Bio Falls Further Behind China

(Graphic: ChatGPT) GlaxoSmithKline (GSK) is set to begin full-scale Phase 3 clinical trials for a long-acting antibody called “felcorekibart,” which originated in China. This comes approximately t…
  • 2026-09-07 08:01:03
  • Minji Son
Technology

i-SENS, Inc., Once a Money Pit, Takes Off… With Margins in the Mid-40s, Can It Achieve Annual Sales of 40 Billion?

i-SENS, Inc.(099190)’s continuous glucose monitoring (CGM) business has begun to secure profitability following its revenue growth. With CGM sales in the first half of this year surpassing last year’s…
  • 2026-09-07 08:01:02
  • NA EUN-KYUNG
Lifestyle

Skylabs Makes a Strong Debut; Samik Pharma and Penetrium Bio Also Surge [K-Bio Pulse]

As the domestic stock market refocuses on solid corporate performance, clinical developments, and tangible commercialization milestones, the biotech sector saw strong capital inflows on September 4, t…
  • 2026-09-07 07:51:04
  • YU JIN-HEE
Lifestyle

SkyLabs Makes Its Mark on First Day of Listing… SAMIK PHARM. Co., LTD. and PenetriumBio Also Rise [Bio Spotlight]

As the domestic securities market has recently been realigning itself around corporate earnings and tangible clinical and commercialization achievements, the biotech sector also saw strong buying inte…
  • 2026-09-07 07:51:03
  • YU JIN-HEE
Lifestyle

“Expanding into the Aesthetics Market… Establishing a 90 Billion Won Production System”

“Building on the solid manufacturing infrastructure established through oral care over-the-counter products and the reputation for quality accumulated over the past 20 years, we are now actively expan…
  • 2026-09-06 08:27:02
  • YU JIN-HEE
Technology

GC Wellbeing and JW Pharmaceutical Rally [K-bio Pulse]

South Korea’s pharmaceutical and biotech sector experienced significant volatility on August 13, driven by growth themes in obesity/medical aesthetics, hair loss, and immuno-oncology. #GCWellbeing sur…
  • 2026-09-05 08:02:02
  • Kim Seung-kwon
prev 21 22 23 24 25 26 27 28 29 30 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea China Japan
English